StopAfib.org is among a group of experts calling today for urgent action to prevent an atrial fibrillation stroke crisis in the Asia-Pacific region. Action for Stroke Prevention, a group of health experts from across the globe, is launching a new report, How Can We Avoid a Stroke Crisis in the Asia-Pacific Region?, at the 18th …
Read More
In honor of National Stroke Awareness Month (May), Team AFib invites you to our inaugural webinar “AFib: When Stroke Strikes”, hosted by the National Stroke Association. A live expert panel will help you learn to recognize and respond quickly to afib stroke signs and symptoms. StopAfib.org is a member of Team AFib. To learn more …
Read More
Dr. John Mandrola shares a great update on the latest info regarding dabigatran (Pradaxa, Pradax). Dr. Mandrola not only treats atrial fibrillation patients, but he has also experienced afib himself. I have become an AF-doctor. That means my most exciting aspect of medicine is terminating AF with watts delivered through a catheter. “Got it.” In …
Read More
Researchers at the Comprehensive Arrhythmia Research and Management Center (CARMA) in Utah have been studying the relationship between atrial fibrillation, atrial fibrosis, and catheter ablation outcomes for many years. Now, they’ve applied their knowledge of quantifying atrial fibrosis to stroke risk assessment and found that the amount of atrial fibrosis, not type of afib, is …
Read More
New research from Denmark shows that CHADS2 underestimates stroke risk. In the study, atrial fibrillation patients who were at intermediate risk with the CHADS2 scoring system had more than twice the stroke rate of those defined by the enhanced CHA2DS2-VASc tool as being at intermediate risk. While CHADS2 deemed 32.3% of patients to have intermediate …
Read More
In this video, Dr. Kenneth Ellenbogen talks about important information presented at the American Heart Association Scientific Sessions 2010. First he talked about the ROCKET AF clinical trial of rivaroxaban, a new drug that is an alternative to warfarin (Coumadin), as well as another alternative, the recently-approved dabigatran. He provided scenarios as to how these drugs …
Read More
Up to 30% of patients could have very late recurrence of atrial fibrillation after catheter ablation, according to research highlighted at the recent Boston AF Symposium. Very late recurrence, which is when atrial fibrillation resumes more than one year after ablation, may be the result of age, gender, type of afib, and existence of other …
Read More
StopAfib.org has published the 2010 Most Popular Atrial Fibrillation News Stories and Videos List. Stroke prevention topped the list and included stories about warfarin (Coumadin) and alternatives such as dabigatran (Pradaxa) and rivaroxaban (Xarelto). Other popular topics included the new European atrial fibrillation guidelines, new antiarrhythmic medications, updates on catheter ablation and afib surgery, and …
Read More
New medical guidelines from the European Society of Cardiology (ESC) incorporating the latest afib research put Europe ahead of the U.S. when it comes to standardized treatment of atrial fibrillation. Stroke prevention and symptom relief are at the heart of the new ESC guidelines, which also make it clear that the risk of stroke for …
Read More
On the heels of the US FDA approving dabigatran, the long-awaited alternative to Coumadin (warfarin), comes word that Health Canada has as well. In Canada, dabigatran is known as PRADAX™. Because this is the first alternative to warfarin in Canada, it is big news for the afib community there. Learn more at: Health Canada Approves …
Read More